Table 1.

Subject demographic data (blood)

	DLE+/SLE+	DLE+/SLE−	Psoriasis	Normal
N	28	35	11	32
Age at visit, yr (SD)	45 (13)	45 (11)	53 (10)	43 (11)
Gender (M/F)	5/23	7/28	2/9	7/35
Ethnicity, No. (%)
Caucasian	6 (21%)	8 (23%)	8 (73%)	16 (38%)
African American	15 (54%)	23 (66%)	0 (0%)	22 (52%)
Hispanic	4 (14%)	3 (9%)	2 (18%)	4 (10%)
Asian	3 (11%)	0 (0%)	1 (9%)	0 (0%)
Other	0 (0%)	1 (3%)	0 (0%)	0 (0%)
CLASI activity score, mean (SD)	9 (9)	6 (5)	N/A	N/A
CLASI damage score, mean (SD)	12 (12)	8 (5)	N/A	N/A
SLEDAI score, mean (SD)	3 (3)	1 (2)	N/A	N/A
PASI score, mean (SD)	N/A	N/A	5 (4)	N/A
Disease Duration, yr (SD)	9 (12)	8 (10)	10 (11)	N/A
Lupus medications at study visit, No. (%)
Topical/Intralesional Corticosteroids	12 (43%)	18 (51%)	3 (27%)	N/A
Topical Immunomodulators	2 (7%)	2 (6%)	0 (0%)	N/A
Hydroxychloroquine	16 (57%)	18 (51%)	0 (0%)	N/A
Chloroquine	3 (11%)	3 (9%)	0 (0%)	N/A
Quinacrine	2 (7%)	4 (11%)	0 (0%)	N/A
Methotrexate	0 (0%)	2 (6%)	0 (0%)	N/A
Prednisone	9 (32%)	1 (3%)	0 (0%)	N/A
Mycophenolate mofetil	7 (25%)	1 (3%)	0 (0%)	N/A
Acitretin	0 (0%)	0 (0%)	1 (9%)	N/A
Ustekinumab	0 (0%)	0 (0%)	1 (9%)	N/A
None	0 (0%)	8 (24%)	8 (73%)	N/A
SLE criteria, No. (%)^a
Malar rash	12 (43%)	1 (3%)	N/A	N/A
Discoid rash	28 (100%)	35 (100%)	N/A	N/A
Photosensitivity	25 (89%)	24 (69%)	N/A	N/A
Oral ulcers	12 (43%)	5 (14%)	N/A	N/A
Arthritis	16 (57%)	4 (11%)	N/A	N/A
Serositis	3 (11%)	0 (0%)	N/A	N/A
Renal disorder	6 (21%)	0 (0%)	N/A	N/A
Hematological disorder	19 (68%)	4 (11%)	N/A	N/A
Anti-nuclear antibody	27 (96%)	8 (23%)	N/A	N/A
Immunological disorder	21 (75%)	0 (0%)	N/A	N/A

Mean # of SLE criteria (SD)	6 (1)	2 (1)	N/A	N/A

None of the DLE patients had neurological disorder.

Abbreviations: CLASI = Cutaneous Lupus Disease Activity and Severity Index; DLE = discoid lupus erythematosus; PASI = Psoriasis Activity and Severity Index; SLE = Systemic Lupus Erythematosus; SLEDAI = Systemic Lupus Erythematosus Disease and Activity Index